Sulbactam and durlobactam

(Xacduro®)

Sulbactam and durlobactam

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormInjection (intravenous; 1 g of sulbactam for injection [1 clear single-dose vial] and 0.5 g of durlobactam for injection [2 amber single-dose vials])
Drug ClassBeta lactamase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Sulbactam and durlobactam (Xacduro) is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years or older.
  • The information on this drug was derived from a single systematic review/meta-analysis study, focusing on its potential effectiveness against infections caused by A. baumannii, including carbapenem-resistant strains.
  • Combining durlobactam with sulbactam enhances the activity against sulbactam-resistant isolates and effectively reverses their resistance, making them susceptible again; this suggests that Xacduro could be a significant option for dealing with multidrug-resistant A. baumannii strains.
  • While the systematic review indicates that Xacduro may be an effective therapeutic option for treating infections caused by multidrug-resistant A. baumannii, it emphasizes the need for future clinical trials to firmly establish its safety and efficacy.
  • No direct comparisons between Xacduro and other antimicrobial agents were provided in terms of safety and effectiveness; however, its implied advantage lies in its specific action towards reversing resistance among certain HABP/VABP causing bacteria, which are difficult to manage with existing therapies.
  • Although specified as suitable for patients aged 18 years or older suffering from HABP/VABP due to multidrug-resistant A. baumannii infection, no further details regarding different population types or subgroup considerations were mentioned.

Product Monograph / Prescribing Information

Document TitleYearSource
Xacduro (sulbactam, durlobactam) Prescribing Information. 2023Entasis Therapeutics Ltd., an affiliate of Innoviva Specialty Therapeutics, Waltham, MA

Systematic Reviews / Meta-Analyses